Analyst Reco. ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
8.8 ^USD	+5.14%		-21.36%	-40.90%

Jun. 02	ALX Oncology Holdings Inc. Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 Aspen-07 Clinical Trial in Patients with Advanced Bladder Cancer	CI
May. 09	ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing	May. 08	MT
Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	Apr. 18	MT
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating	Mar. 13	MT
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating	Mar. 11	MT
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating	Mar. 08	MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10	Mar. 08	MT
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $18 From $8	Dec. 08	MT
Stifel Trims ALX Oncology Holdings' Price Target to $10 From $11, Maintains Buy Rating	Nov. 14	MT
Piper Sandler Raises Price Target on ALX Oncology to $11 From $8, Maintains Overweight Rating	23-10-11	MT
UBS Adjusts ALX Oncology Price Target to $27 From $29, Maintains Buy Rating	23-10-04	MT
Cantor Fitzgerald Raises Price Target on ALX Oncology to $23 From $18, Maintains Overweight Rating	23-10-04	MT
Cantor Fitzgerald Cuts Price Target on ALX Oncology Holdings to $18 From $22, Maintains Overweight Rating	23-08-14	MT
HC Wainwright Adjusts ALX Oncology Price Target to $16 From $30, Maintains Buy Rating	23-08-11	MT
UBS Adjusts ALX Oncology's Price Target to $29 From $31, Maintains Buy Rating	23-03-15	MT
Credit Suisse Lowers ALX Oncology Holdings' Price Target to $34 From $38, Keeps Outperform Rating	23-03-10	MT
HC Wainwright Adjusts ALX Oncology Price Target to $30 From $65, Maintains Buy Rating	23-03-10	MT
HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains Buy Rating	22-11-09	MT
UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating	22-08-26	MT
Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating	22-08-09	MT
Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating	22-08-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Analyst Reco.

Filters